ATE330589T1 - Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege - Google Patents

Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege

Info

Publication number
ATE330589T1
ATE330589T1 AT01976492T AT01976492T ATE330589T1 AT E330589 T1 ATE330589 T1 AT E330589T1 AT 01976492 T AT01976492 T AT 01976492T AT 01976492 T AT01976492 T AT 01976492T AT E330589 T1 ATE330589 T1 AT E330589T1
Authority
AT
Austria
Prior art keywords
treatment
pharmaceutical composition
composition containing
inflammatory diseases
respiratory tract
Prior art date
Application number
AT01976492T
Other languages
English (en)
Inventor
Louise Elizabeth Donnelly
Peter John Barnes
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Application granted granted Critical
Publication of ATE330589T1 publication Critical patent/ATE330589T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01976492T 2000-10-19 2001-10-19 Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege ATE330589T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/694,108 US6878751B1 (en) 2000-10-19 2000-10-19 Administration of resveratrol to treat inflammatory respiratory disorders

Publications (1)

Publication Number Publication Date
ATE330589T1 true ATE330589T1 (de) 2006-07-15

Family

ID=24787430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01976492T ATE330589T1 (de) 2000-10-19 2001-10-19 Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege

Country Status (12)

Country Link
US (1) US6878751B1 (de)
EP (1) EP1326595B1 (de)
AT (1) ATE330589T1 (de)
AU (1) AU2001295760A1 (de)
CA (1) CA2425420C (de)
CY (1) CY1107498T1 (de)
DE (1) DE60121012T2 (de)
DK (1) DK1326595T3 (de)
ES (1) ES2266271T3 (de)
PT (1) PT1326595E (de)
WO (1) WO2002032410A2 (de)
ZA (1) ZA200302727B (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100586428C (zh) 2001-11-02 2010-02-03 加州大学校务委员会 用于预防和治疗炎性疾病,自体免疫性疾病,和移植排斥的组成物及其制药用途
US20070218151A1 (en) * 2002-03-12 2007-09-20 Universidade Do Estado Do Rio De Janeiro Process for obtention of decoctions of Vitis labrusca and Vitis vinifera skins
EP1369113B1 (de) * 2002-06-06 2006-11-22 CHIESI FARMACEUTICI S.p.A. Lösung von Wirkstoffen in HFA-Treibgasen mittels Emulsionen
MXPA04012560A (es) * 2002-06-13 2005-10-19 Wyeth Corp Inhibidores de la actividad genica inflamatoria y biosintesis de colesterol.
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20040105821A1 (en) * 2002-09-30 2004-06-03 Howard Bernstein Sustained release pharmaceutical formulation for inhalation
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20060252707A1 (en) * 2003-05-28 2006-11-09 Universite De Liege Pharmaceutical composition for the treatment and/or the prevention of atherosclerosis from infectious origin
JP2007509035A (ja) * 2003-10-10 2007-04-12 レスバーロジックス コーポレイション Ｅｇｒ−１エンハンサー要素に関連する疾患の処置
WO2005069998A2 (en) * 2004-01-20 2005-08-04 Brigham Young University Technology Transfer Office Novel sirtuin activating compounds and methods for making the same
JP5140416B2 (ja) * 2004-06-21 2013-02-06 ユニヴァーシティー オブ ミシシッピ 望ましい化学的官能基を有する抗がん及び抗原虫ジヒドロアーテミシニン及びジヒドロアーテミシテンダイマー
CA2597845A1 (en) * 2005-02-25 2006-08-31 Isis Pharmaceuticals, Inc. Compositions and their uses directed to il-4r alpha
WO2006102407A2 (en) 2005-03-23 2006-09-28 Children's Medical Center Corporation Orthotic device for preventing and/or correcting deformational posterior plagiocephaly
CA2609549A1 (en) * 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060293261A1 (en) * 2005-06-24 2006-12-28 Taisho Pharmaceutical Co., Ltd. Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli
EP1898897A2 (de) * 2005-07-07 2008-03-19 Sirtris Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung oder prävention von adipositas, insulinwiderstandserkrankungen und mit den mitochondrien zusammenhängenden krankheiten
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CA2624796A1 (en) * 2005-10-03 2007-04-12 Isis Pharmaceuticals, Inc. Combination therapy using budesonide and antisense oligonucleotide targeted to il-4 receptor alpha
EP1978933A2 (de) * 2005-12-15 2008-10-15 Acusphere, Inc. Verfahren zur herstellung von pharmazeutischen formulierungen auf teilchenbasis zur oralen verabreichung
EP1969143A4 (de) * 2005-12-20 2009-07-22 Isis Pharmaceuticals Inc Auf il-4-rezeptor alpha als ziel gerichtete doppelsträngige nukleinsäuremoleküle
DK1962869T3 (da) * 2005-12-21 2013-06-24 Solaeromed Inc Behandling af luftvejssygdomme
US20070207201A1 (en) * 2006-03-06 2007-09-06 Wyeth Liquid and Semi-Solid Pharmaceutical Formulations and Processes
FR2898493B1 (fr) * 2006-03-16 2008-08-08 Af Consulting Compositions cosmetiques, pharmaceutiques, alimentaires et veterinaires dont l'action d'activation de genes de type sirtuin permet de retarder le vieillissement des mammiferes et ses effets nefastes
DE602006013787D1 (de) * 2006-03-28 2010-06-02 Epitech Group Srl Eine Pharmazeutische Zusammensetzung zur Behandlung von Pathologien, die durch die allgemeine Immunantwort verursacht werden
US8524654B2 (en) * 2007-05-21 2013-09-03 The Uab Research Foundation Prolyl endopeptidase inhibitors for reducing or preventing neutrophilic inflammation
US20100210735A1 (en) * 2007-08-06 2010-08-19 University Of Florida Research Foundation, Inc. Modulating the Activity of Nuclear Receptors in Order to Treat Hypoxia-Related Disorders
WO2009026473A2 (en) * 2007-08-21 2009-02-26 Hollis-Eden Pharmaceuticals, Inc. Stabilized therapeutic compositions and formulations
EP2671614A1 (de) * 2007-12-21 2013-12-11 University of Rochester Molekulare Ziele zur Behandlung von Entzündungen
BRPI0907423A2 (pt) 2008-01-11 2020-10-27 Reata Pharmaceuticals, Inc. composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto
GB0801032D0 (en) * 2008-01-21 2008-02-27 Univ York Immune modulation
WO2009108999A1 (en) * 2008-03-03 2009-09-11 Ross Stewart Grant Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
WO2009146218A2 (en) * 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
US8341614B2 (en) * 2008-06-06 2012-12-25 Apple Inc. Memory management for closures
EP2309860B1 (de) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclische cyanoenone und anwendungsverfahren
ES2362065B1 (es) * 2009-12-15 2012-05-18 Consejo Superior De Investigaciones Cient�?Ficas (Csic) Compuestos con actividad antiinflamatoria.
DK2558105T3 (da) 2010-04-12 2020-01-27 Reata Pharmaceuticals Inc Bardoxolonmethyl til behandling af fedme
CN101791292A (zh) * 2010-04-13 2010-08-04 江庆澜 虎杖苷喷雾剂在作为哮喘治疗药物中的应用
US20120121730A1 (en) * 2010-10-07 2012-05-17 Trinity Laboratories, Inc. Pharmaceutical and nutraceutical compositions for treating respiratory disease and associated phlegm
CN103596929B (zh) 2010-12-17 2016-10-19 里亚塔医药公司 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
MX348862B (es) 2011-03-11 2017-07-03 Reata Pharmaceuticals Inc Derivados c4-monometil triterpenoides y sus metodos de uso.
TWI623548B (zh) 2012-04-27 2018-05-11 瑞塔醫藥有限責任公司 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２-二氟基丙醯胺衍生物、多晶型及其使用方法
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
WO2014018874A1 (en) 2012-07-26 2014-01-30 The William M. Yarbrough Foundation Method for treating skin cancer
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
JP6243428B2 (ja) 2012-09-10 2017-12-06 リアタ ファーマシューティカルズ インコーポレイテッド オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法
WO2014113404A1 (en) * 2013-01-15 2014-07-24 Nusirt Sciences, Inc. Treating pulmonary conditions
CN105813690A (zh) 2013-08-21 2016-07-27 协和大学 树状聚合物-白藜芦醇复合物
WO2016179328A1 (en) 2015-05-05 2016-11-10 Children's Medical Center Corporation Devices and methods for supporting and containing premature babies and small-for-age infants
JP7074674B2 (ja) 2015-09-23 2022-05-24 リアタ ファーマシューティカルズ インコーポレイテッド Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
ES2673942B1 (es) 2016-11-23 2019-04-09 Consejo Superior Investigacion Compuestos acilados para el tratamiento de patologias oculares
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
JP2023511370A (ja) 2020-01-22 2023-03-17 シーロス セラピューティクス， インコーポレイテッド Ｎｍｄａ拮抗薬の副作用の低減
EP4019013A1 (de) 2020-12-24 2022-06-29 Bionotus GCV Behandlung von lungenerkrankungen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1577196A (en) * 1977-06-03 1980-10-22 Ile De France Compositions containing erythromycin and metoclopramide
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US5411986A (en) 1993-03-12 1995-05-02 The Johns Hopkins University Chemoprotective isothiocyanates
IT1276225B1 (it) 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US5972995A (en) 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
US6414037B1 (en) 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
US6022901A (en) 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
CA2339049C (en) 1998-09-08 2010-02-23 Cornell Research Foundation, Inc. Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors
AU1853000A (en) 1998-12-24 2000-07-31 1333366 Ontario Inc. A composition useful to treat periodontal disease
PE20010540A1 (es) 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
IT1318425B1 (it) 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro Impiego del resveratrolo per il trattamento di eczema desquamativo,acne e psoriasi.

Also Published As

Publication number Publication date
CY1107498T1 (el) 2013-03-13
CA2425420C (en) 2010-10-12
ZA200302727B (en) 2004-04-08
DK1326595T3 (da) 2006-10-23
ES2266271T3 (es) 2007-03-01
CA2425420A1 (en) 2002-04-25
AU2001295760A1 (en) 2002-04-29
EP1326595B1 (de) 2006-06-21
WO2002032410A2 (en) 2002-04-25
PT1326595E (pt) 2006-09-29
US6878751B1 (en) 2005-04-12
DE60121012T2 (de) 2007-01-04
DE60121012D1 (de) 2006-08-03
WO2002032410A3 (en) 2002-08-01
EP1326595A2 (de) 2003-07-16

Similar Documents

Publication Publication Date Title
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
RU2004122921A (ru) Композиция для ингаляции
CY1122533T1 (el) Ανακινρα για χρηση στην αντιμετωπιση συνδρομου αποφρακτικης βρογχιολιτιδας
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
HUS1900056I1 (hu) Légzési rendellenességek kezelésére alkalmas, glikopirrolát tartalmú száraz porkészítményt tartalmazó inhaláló készülék és alkalmazása
DE60128258D1 (de) Indanylderivate zur Behandlung von Atemwegserkrankungen
BR0008699A (pt) Combinações de formoterol e furoato demometasona para asma
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
BR0008276A (pt) Combinações de formoterol e propionato de fluticasona para asma
ATE339954T1 (de) Kombinationen von formoterol und tiotropium-salz
DE60216588D1 (de) Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
RU2006132036A (ru) Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей
JP2008533072A5 (de)
HRP20120286T1 (hr) Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti
NO20054767L (no) Sammensetninger omfattende apomorfin for inhalering i lunge
AR039409A1 (es) Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.
JPH05509300A (ja) 上部気道における粘液分泌促進剤としてフェニルプロパノールアミンの使用
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
JP2008115167A (ja) トラネキサム酸を含有する気道杯細胞過形成抑制剤
EA200500864A1 (ru) Новый, содержащий тиотропий порошковый препарат для ингаляции
BR0308984A (pt) Formulações em pó adequadas para inalação
JP2009506029A5 (de)
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
JP2010189301A (ja) 新型インフルエンザ感染症に対する医薬組成物およびその利用
ATE475409T1 (de) Mikroemulsionsformulierungen mit bestimmten substanz p antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1326595

Country of ref document: EP